Overview

A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients

Status:
Completed

Trial end date:
2008-11-01

Target enrollment:

Participant gender:

Summary

To evaluate the safety of IV conivaptan in stable euvolemic or hypervolemic cirrhotic patients, and to characterize the effects of IV conivaptan on the hepatic hemodynamic response in patients with cirrhosis.

Phase:

Phase 2

Details

Lead Sponsor:

Cumberland Pharmaceuticals

Treatments:

Conivaptan